Metformin in Safety and Efficacy in Gouty Patients

Phase 2RecruitingNCT06924658

Mostafa Bahaa70 enrolled

Overview

The most frequent crystal arthropathy is gout, which is also the most prevalent cause of inflammatory arthritis. Gouty Patients frequently have excruciating pain and swelling in their joints. Gout is linked to decreased health-related quality of life and functional disability. Gout and its associated diseases have been shown to have a significant impact on patients mortality and morbidities. Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Gout

Interventions

placebo

MetforminDRUG

Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Gouty patients clinically diagnosed as gouty arthritis based on the American College of Rheumatology/European League Against Rheumatism criteria of gout. Exclusion Criteria: * Systemic disorders such as cardiovascular, neurological, coronary artery disease. * Hypertension, hyperlipidemia, diabetes mellitus, active infections. * Other inflammatory or autoimmune diseases. * Patients on biologics, * Cases with hypersensitivity to metformin and those with impaired liver and kidney functions.

Outcomes

Primary Outcomes

- Clinical assessment of disease activity

\- Clinical assessment of disease activity by assessing patient and physician VAS visual analog scale (0-10 cm);

Time frame: 3 months